Asher Biotherapeutics Company Profile

Background

Asher Biotherapeutics, founded in 2019 and headquartered in South San Francisco, California, is a biotechnology company dedicated to developing precisely targeted immunotherapies for cancer, autoimmune, and infectious diseases. The company's mission is to harness its proprietary cis-targeting platform to selectively activate specific immune cell types, thereby enhancing therapeutic efficacy while minimizing off-target effects and associated toxicities.

Key Strategic Focus

Asher Bio's strategic focus centers on the development of immunotherapies that precisely engage desired immune cell subsets. Utilizing their cis-targeting platform, the company designs therapies that require the engagement of two molecules on the same cell: an immunomodulatory receptor and a cell-type-specific marker. This approach ensures activation occurs exclusively in the intended immune cells, thereby reducing undesirable effects. The primary markets targeted include oncology, with a particular emphasis on solid tumors, as well as autoimmune and infectious diseases.

Financials and Funding

Since its inception, Asher Bio has successfully secured substantial funding to advance its pipeline:

Series A Financing (March 2021): Raised $55 million, led by Third Rock Ventures, with participation from Boxer Capital of Tavistock Group, Invus, Y Combinator, and MBC Biolabs.

Series B Financing (September 2021): Secured $108 million, led by Wellington Management Company LLP, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace, and Alexandria Venture Investments, along with existing investors.

Series C Financing (April 2024): Closed a $55 million round, led by RA Capital Management, with participation from AstraZeneca, Bristol Myers Squibb, and existing investors.

The capital raised is intended to fund the clinical development of lead programs, particularly AB248, and to advance additional cis-targeted product candidates through various stages of development.

Pipeline Development

Asher Bio's pipeline is anchored by its lead program and supported by additional candidates:

Etakafusp Alfa (AB248): A CD8+ T cell-selective interleukin-2 (IL-2) therapy engineered to activate and expand tumor-killing CD8+ T cells while avoiding natural killer (NK) cells and regulatory T (Treg) cells. AB248 is currently in an open-label Phase 1a/1b clinical trial, evaluating its safety and efficacy as a monotherapy and in combination with pembrolizumab in patients with recurrent locally advanced or metastatic solid tumors, including melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and squamous cell carcinoma of the head and neck (SCCHN).

AB821: A CD8-targeted interleukin-21 (IL-21) designed to selectively activate CD8+ T cells via a pathway distinct from IL-2, enhancing their cytotoxic function.

AB359: A CD8-targeted IL-2 therapy for chronic hepatitis B virus (HBV), currently in preclinical development.

Technological Platform and Innovation

Asher Bio's proprietary cis-targeting platform is a cornerstone of its innovation, enabling the development of immunotherapies with unprecedented selectivity:

Cis-Targeting Mechanism: Therapies are designed to engage two molecules on the same immune cell: an immunomodulatory receptor and a specific target that directs the therapy to the desired immune cell type. This dual engagement ensures activation occurs exclusively in the intended cells, optimizing efficacy and minimizing toxicity.

Proprietary Technologies: The platform allows for the creation of fusion proteins that combine a reduced potency immunomodulator with an antibody targeting a specific immune cell marker, ensuring selective activation.

Scientific Methodologies: The company employs a systematic process to discover novel cis-targeted therapies, which can be applied universally to multiple immunomodulatory molecules and target cell types.

Leadership Team

Asher Bio's leadership comprises experienced professionals with diverse backgrounds:

Craig Gibbs, Ph.D., MBA: Chief Executive Officer and Board Member. Dr. Gibbs brings extensive experience in biotechnology leadership and strategic development.

Ivana Djuretic, Ph.D.: Co-Founder, Chief Scientific Officer, and Board Member. Dr. Djuretic has a robust background in immunology and therapeutic development.

Andy Yeung, Ph.D.: Co-Founder and Chief Technology Officer. Dr. Yeung specializes in protein engineering and therapeutic innovation.

Kyle Elrod: Chief Operating Officer. Mr. Elrod oversees operational strategies and execution.

David Kaufman, M.D., Ph.D.: Interim Head, Clinical and Translational Research. Dr. Kaufman leads clinical development initiatives.

Sheldon Okada: Vice President, Commercial and Business Strategy. Mr. Okada focuses on commercial strategy and business development.

Leadership Changes

In January 2023, Asher Bio appointed Elaine Sun as an independent director to its Board, bringing additional expertise to the company's governance.

Competitor Profile

Market Insights and Dynamics

The immunotherapy market is experiencing significant growth, driven by advancements in targeted therapies and increasing prevalence of cancer and autoimmune diseases. The demand for more selective and effective treatments continues to rise, positioning companies like Asher Bio at the forefront of innovation.

Competitor Analysis

Key competitors in the targeted immunotherapy space include:

Nektar Therapeutics: Focuses on cytokine-based therapies, including IL-2 variants, aiming to enhance immune responses against tumors.

Synthorx (acquired by Sanofi): Developed engineered cytokines to selectively modulate immune cells, similar to Asher Bio's approach.

AstraZeneca: Engages in the development of immuno-oncology therapies, including bispecific antibodies and checkpoint inhibitors.

Strategic Collaborations and Partnerships

Asher Bio has established several strategic collaborations to enhance its development capabilities:

AstraZeneca: Entered into a clinical supply agreement to evaluate etakafusp alfa in combination with rilvegostomig, AstraZeneca's investigational PD-1/TIGIT bispecific antibody, in patients with advanced or metastatic NSCLC.

Lonza: Collaborated for the manufacturing of AB248, leveraging Lonza's expertise in complex protein production to support clinical supply needs.

Operational Insights

Asher Bio's strategic considerations include:

Differentiation: Leveraging its cis-targeting platform to develop therapies with superior selectivity, aiming to overcome limitations of existing immunotherapies.

Market Position: Focusing on unmet needs in oncology and other diseases to establish a strong foothold in the immunotherapy market.

Competitive Advantages: The ability to precisely target immune cell subsets offers potential improvements in efficacy and safety profiles over competitors.